Metastatic Cancer (Different Solid Tumour Types) Clinical Trial
— VOTRAGEOfficial title:
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
| Verified date | August 2018 |
| Source | Institut Claudius Regaud |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is an open-label, multicenter, non-randomized, phase 1 dose escalation clinical trial to
determine the MTD (Maximal Tolerated Dose) of Pazopanib in a population of frail elderly
patients, selected according to the International Society of Geriatric Oncology
(SIOG)classification (Group 2).
It is expected that a total number of 30 patients maximum will be enrolled in the study on 30
months : 18 months accrual - 12 months follow up.
Eligible patients will be enrolled into a standard 3+3 design with a starting dose of
Pazopanib administered orally at 400 mg per day, in 28-day cycles. Then, further dose levels
will be explored.
Toxicity of the schedule will be assessed during the first cycle. Patients will receive study
medication until disease progression. After treatment discontinuation, patients will be
followed during one year.
| Status | Terminated |
| Enrollment | 18 |
| Est. completion date | March 2018 |
| Est. primary completion date | September 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 75 Years and older |
| Eligibility |
Inclusion Criteria: 1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up. 2. Age = to 75 years old 3. Patient with metastatic cancer among renal cell carcinoma, non small cell lung cancer, pancreatic neuroendocrine cancer, sarcoma , ovarian cancer , thyroid cancer, bladder cancer or breast cancers, who cannot receive any treatment with curative intent. 4. WHO PS = 2, 5. Life expectancy = 3 months, 6. Group 2 (vulnerable) according to SIOG classification, 7. Adequate organ system function as defined in provided Table Exclusion Criteria: 1. Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed at low risk for recurrence by his/her treating physician, 2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. 3. Criteria of group 3 according to SIOG classification, 4. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: •Active peptic ulcer disease •Known intraluminal metastatic lesion/s with risk of bleeding •Inflammatory bowel disease (e.g. ulcerative colitis, crohn's disease), or other gastrointestinal conditions with increased risk of perforation •History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment. 5. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: •Malabsorption syndrome •Major resection of the stomach or small bowel. 6. Presence of uncontrolled infection. 7. Corrected QT interval (QTc) > 480 msecs using Bazett's formula 8. Anti-coagulants treatment (preventive or curative) 9. History of any one or more of the following cardiovascular conditions within the past 6 months: • Cardiac angioplasty or stenting • Myocardial infarction • Unstable angina • Coronary artery bypass graft surgery - Symptomatic peripheral vascular disease - Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) 10. Poorly controlled hypertension 11. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. 12. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer 13. Evidence of active bleeding or bleeding diathesis. 14 Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels 15. Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug. 16. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. 17. Unable or unwilling to discontinue use of prohibited medications list in Appendix 7 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study 18. Treatment with any of the following anti-cancer therapies: - radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR - chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib 19. Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity, except alopecia. 20. Patient not affiliated with social system in France. 21. Patient deprived of liberty or under guardianship |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital Saint André | Bordeaux | |
| France | Centre François BACLESSE | Caen | |
| France | Centre Léon BERARD | Lyon | |
| France | Institut Claudius REGAUD | Toulouse |
| Lead Sponsor | Collaborator |
|---|---|
| Institut Claudius Regaud | Novartis |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Dose limiting toxicity (DLT) incidence (according DLT definition) during the first treatment cycle with pazopanib (28 days) | The MTD (Maximum Tolerated Dose) is defined as the highest dose level for which 6 patients were treated with a maximum of 1 patient presenting a DLT during the first cycle of treatment | 7.5 years | |
| Secondary | Safety and tolerability assessments using the descriptions and grading scales found in the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0 NCI | 7.5 years | ||
| Secondary | Measure of Pazopanib plasma concentration during treatment period (objective : assessment of pharmacokinetics of Pazopanib in this population) | Plasma concentrations of pazopanib will be determined using a validated LC-MS-MS method - | .8 time points (cycle 1 Day 1), 3 time points (cycle 1 D15) and 1 pre dose time point each day 1 of the following cycles (over a period of 7.5 years for measures in all patients) | |
| Secondary | Geriatric criteria measured by comprehensive geriatric assessment which evaluate medical, functional and psychosocial aspects of elderly patients | The impact of treatment on the geriatric assessment will be done using : G8 : screening test ADL: Activities Daily Living IADL: Instrumental Activities Daily Living MMSE: Mini-mental State Examination SPPB: Short Physical Performance Battery MNA: Mini-nutritional Assessment CAM: Confusion Assessment Method GDS-15: Geriatric Depression Scale CIRS-G: Cumulative Illness Rating Scale for Geriatrics, |
7.5 years | |
| Secondary | Rate of objective response according to RECIST criteria | Tumor assessment will be performed at screening visit, every 2 cycles and at the end of study visit and anytime if clinically indicated | 7.5 years |